Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin in CD30-positive Lymphoproliferative Disorders
NCT01352520Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2011
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in primary cutaneous anaplastic large cell lymphoma (pcALCL), mycosis fungoides (MF) and lymphomatoid papulosis (LyP), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Response Rate at 12 months. Started Jun 2011; status: active, not recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
primary cutaneous anaplastic large cell lymphoma (pcALCL)mycosis fungoides (MF)lymphomatoid papulosis (LyP)
Beyond the preview
Go deeper on NCT01352520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01352520.